Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables: 2010-2024

Historic Receivables for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $41.5 million.

  • OptimizeRx's Receivables rose 1119.74% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 1119.74%. This contributed to the annual value of $41.5 million for FY2024, which is 207.18% down from last year.
  • OptimizeRx's Receivables amounted to $41.5 million in FY2024, which was down 207.18% from $42.3 million recorded in FY2023.
  • OptimizeRx's 5-year Receivables high stood at $42.3 million for FY2023, and its period low was $18.6 million during FY2020.
  • For the 5-year period, OptimizeRx's Receivables averaged around $31.0 million, with its median value being $26.9 million (2021).
  • Per our database at Business Quant, OptimizeRx's Receivables soared by 15131.92% in 2020 and then plummeted by 436.03% in 2022.
  • OptimizeRx's Receivables (Annual) stood at $18.6 million in 2020, then soared by 44.35% to $26.9 million in 2021, then dropped by 4.36% to $25.7 million in 2022, then surged by 64.46% to $42.3 million in 2023, then fell by 2.07% to $41.5 million in 2024.
  • Its Receivables stands at $41.5 million for FY2024, versus $42.3 million for FY2023 and $25.7 million for FY2022.